AZN: מכפיל מחיר להכנסות AstraZeneca Plc

The calculated price-to-sales ratio helps identify the overvaluation of AstraZeneca PLC (AZN) assets, based on the high margins of its oncology drugs. Business growth is driven by expansion into biopharmaceuticals and acquisitions. Leadership in the ESG agenda is confirmed by the transition to carbon-negative production. The current metric stands at 4.60, allowing investors to find an optimal entry point into the asset.

AstraZeneca PLC (AZN) is developing a high-tech ecosystem in rare disease therapy and oncology, where revenue growth depends on new drug approvals and regulatory pricing policies. By analyzing the price-to-sales ratio, an investor compares market capitalization with annual turnover to determine the asset's degree of overbought status relative to historical averages and to assess the business's resilience to market corrections.